Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Hematology · Chronic Myelomonocytic Leukemia

Is CMML Inherited? Should My Family Get Genetic Testing?

At a Glance

CMML is usually not inherited: more than 95% of cases involve mutations acquired during a person’s lifetime. Healthy relatives generally do not need routine testing, but genetic counseling and confirmatory non-blood testing may be appropriate when family-history red flags or a possible DDX41 variant are present.

For the vast majority of people, chronic myelomonocytic leukemia (CMML) is not an inherited condition, and healthy family members do not need to be routinely tested for it [1].

When you are diagnosed with CMML, your care team will likely run molecular genetic tests on your blood or bone marrow to help guide your prognosis and treatment. These tests usually reveal genetic mutations with names like TET2, SRSF2, ASXL1, or RAS [1]. It is completely natural to see the word “mutation” and worry that you might have passed this disease to your children or inherited it from your parents. However, more than 95% of patients with CMML have somatic mutations [1]. This means the genetic changes were acquired during your lifetime in your blood-forming cells, rather than being passed down through your family [1]. Finding one of these common CMML mutations in your blood is not evidence that your unaffected relatives carry an inherited risk [2].

The Rare Exception: Inherited Predisposition

In a small percentage of cases, CMML and related blood disorders can be linked to an inherited predisposition [3]. These are caused by pathogenic germline variants—genetic changes that you are born with and that are present in every cell of your body [3].

The most well-recognized gene associated with an inherited risk for adult myeloid neoplasms (a group of blood cancers that includes CMML) is called DDX41 [4]. However, it is not the only one; specialists may also look for changes in genes like RUNX1, GATA2, CEBPA, or ETV6 depending on your personal and family history [5][4]. Having an inherited predisposition means there is a susceptibility or higher risk for developing blood cancers, not a 100% certainty that the cancer will occur [6].

You and your doctor might consider the possibility of an inherited predisposition if you have any of these “red flags”:

  • A personal or family history of multiple blood cancers (like myelodysplastic syndrome, acute myeloid leukemia, or CMML) [7].
  • A lifelong history of unexplained low blood counts (cytopenias) or bone marrow failure [8].
  • Unusually young age at diagnosis, or multiple generations in your family with blood diseases [8][9].
  • A suspected variant found on your initial blood or bone marrow test that is known to sometimes be inherited (such as DDX41) [4].

Because families can be small, or relatives’ medical histories might be unknown, an inherited predisposition can occasionally be present even without a striking family history [8].

Why Standard Testing Isn’t Enough

If your doctor suspects an inherited condition, standard blood or bone marrow molecular tests cannot give a definitive answer. Blood and bone marrow contain malignant cells or cells with acquired somatic mutations that can mimic an inherited trait [10][11]. Even a cheek swab or saliva test can be contaminated by these blood cells [6].

To confirm a true germline variant, doctors must test tissue that is not affected by the blood cancer [10]. The “gold standard” for this is testing cultured skin fibroblasts, which requires a small skin punch biopsy (sometimes done at the same time as a bone marrow biopsy) [10][12]. These skin cells must be grown in a lab, so results can take several weeks [12].

It is also important to note that not every “mutation” found on a test is dangerous. Some are harmless, and some are “variants of uncertain significance” (VUS) [4]. A VUS should not be used to make medical decisions or to test relatives [4].

Should My Relatives Be Tested?

Broad genetic screening of healthy relatives for CMML is not recommended [6]. However, if you have red flags for a hereditary syndrome, your doctor may refer you to a genetic counselor [7].

A genetic counselor can explain what the results might mean for you and your family, address privacy and insurance concerns, and discuss whether testing minor children is appropriate [7]. If a pathogenic germline variant is confirmed in you via a skin biopsy, the counselor can then coordinate targeted cascade testing—a process where your at-risk relatives are offered genetic counseling and testing specifically for that one confirmed familial variant [6][13].

Important exception for stem-cell donors: If a family member (like a sibling or child) is being considered as a stem-cell donor for your bone marrow transplant, it is critical to tell the transplant team if there is any known or suspected familial mutation [14]. The related donor should be evaluated and tested using a non-blood sample [15]. If a donor carries the same pathogenic germline variant, their donated blood-forming cells could create a risk of donor-derived leukemia or other severe transplant complications for you [14].

Common questions in this guide

Does having a CMML mutation mean I inherited the disease?
CMML is usually not inherited. More than 95% of people with CMML have somatic mutations, meaning the changes developed during life in blood-forming cells rather than being passed down from a parent. These common CMML mutations do not by themselves show that children, siblings, or parents carry an inherited risk.
When should healthy relatives consider genetic testing for CMML risk?
Routine genetic testing of healthy relatives is not recommended for CMML. Testing may be appropriate when a person with CMML has a strong family history of blood cancers, lifelong low blood counts, an unusually young diagnosis, or a confirmed inherited variant. A genetic counselor can help decide who should be tested and what the results could mean.
What signs suggest that CMML may be linked to an inherited predisposition?
Warning signs include multiple relatives with leukemia, myelodysplastic syndrome, or CMML; blood disorders across generations; lifelong unexplained low blood counts or bone marrow failure; and an unusually young age at diagnosis. A possible inherited variant such as DDX41 can also prompt evaluation. An inherited predisposition raises risk but does not guarantee that cancer will develop.
Why might blood, saliva, or a cheek swab be unable to confirm an inherited variant?
Blood and bone marrow can contain leukemia cells or acquired mutations that make an inherited change difficult to identify. Cheek swabs and saliva can also be contaminated by blood cells. Confirmation usually requires a non-blood sample, often obtained through a small skin punch biopsy with skin cells grown in a laboratory; results may take several weeks.
What happens if testing confirms an inherited CMML-related variant?
Relatives who may carry the same disease-causing inherited variant can be offered targeted genetic counseling and testing. This process is called cascade testing and is different from broad screening of every healthy family member. An unclear genetic change, called a variant of uncertain significance, should not be used to test relatives or make medical decisions.
Should a relative being considered as a stem-cell donor have special testing?
Tell the transplant team about any known or suspected familial mutation before a sibling or child is considered as a stem-cell donor. The potential donor should be evaluated with a non-blood sample, because using cells from a donor who carries the same harmful inherited variant can increase the risk of donor-derived leukemia or other serious transplant complications.

Get notified when new evidence is published on chronic monocytic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.

    Patnaik MM, Tefferi A

    American journal of hematology 2024; (99(6)):1142-1165 doi:10.1002/ajh.27271.

    PMID: 38450850
  2. 2

    Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.

    Patnaik MM, Tefferi A

    American journal of hematology 2022; (97(3)):352-372 doi:10.1002/ajh.26455.

    PMID: 34985762
  3. 3

    Genetic complexity of chronic myelomonocytic leukemia.

    Patel AB, Deininger MW

    Leukemia & lymphoma 2021; (62(5)):1031-1045 doi:10.1080/10428194.2020.1856837.

    PMID: 33337259
  4. 4

    DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.

    Quesada AE, Routbort MJ, DiNardo CD, et al.

    American journal of hematology 2019; (94(7)):757-766 doi:10.1002/ajh.25486.

    PMID: 30963592
  5. 5

    Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison.

    Kao HW, Kuo MC, Ou CW, et al.

    The Journal of pathology 2025; (265(4)):437-447 doi:10.1002/path.6396.

    PMID: 39905935
  6. 6

    Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications.

    Godley LA, DiNardo CD, Bolton K

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2024; (44(3)):e432218 doi:10.1200/EDBK_432218.

    PMID: 38768412
  7. 7

    Recognition of familial myeloid neoplasia in adults.

    Brown AL, Churpek JE, Malcovati L, et al.

    Seminars in hematology 2017; (54(2)):60-68 doi:10.1053/j.seminhematol.2016.11.003.

    PMID: 28637618
  8. 8

    Hereditary Hematopoietic Malignancies: Considerations for Optimizing Diagnosis and Management.

    Trottier AM, Cunningham L, Godley LA

    Current oncology reports 2025; (27(8)):1019-1030 doi:10.1007/s11912-025-01699-7.

    PMID: 40563019
  9. 9

    How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms.

    Baliakas P, Tesi B, Cammenga J, et al.

    HemaSphere 2024; (8(8)):e145 doi:10.1002/hem3.145.

    PMID: 39139355
  10. 10

    Standardized Culture of Skin Fibroblasts From Punch Biopsies for Germline DNA Isolation in Myeloid Malignancies: A Practical Bedside-to-Laboratory Approach.

    Kour P, Kumari N, Kaushal N, et al.

    Bio-protocol 2025; (15(19)):e5469 doi:10.21769/BioProtoc.5469.

    PMID: 41080449
  11. 11

    Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.

    Ceyhan-Birsoy O, Selenica P, Chui MH, et al.

    Journal of the National Cancer Institute 2021; (113(12)):1751-1760 doi:10.1093/jnci/djab117.

    PMID: 34240179
  12. 12

    Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders.

    DeRoin L, Cavalcante de Andrade Silva M, Petras K, et al.

    Human mutation 2022; (43(7)):950-962 doi:10.1002/humu.24374.

    PMID: 35419889
  13. 13

    Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up.

    Baliakas P, Tesi B, Wartiovaara-Kautto U, et al.

    HemaSphere 2019; (3(6)):e321 doi:10.1097/HS9.0000000000000321.

    PMID: 31976490
  14. 14

    How I diagnose myeloid neoplasms with germline predisposition.

    Patel N, Calvo KR

    American journal of clinical pathology 2023; (160(4)):352-364 doi:10.1093/ajcp/aqad075.

    PMID: 37458302
  15. 15

    Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea.

    Yun J, Song H, Kim SM, et al.

    Human genomics 2023; (17(1)):13 doi:10.1186/s40246-023-00458-8.

    PMID: 36814285

This page is for informational purposes only and does not constitute medical advice. Discuss your personal and family history, testing options, and any potential stem-cell donor concerns with your hematologist or a genetic counselor.